Menu Search
Equities

ZYUS Life Sciences Corp

ZLSCF:PKC

ZYUS Life Sciences Corp

Actions
  • Price (USD)0.74
  • Today's Change0.00 / 0.00%
  • Shares traded55.00
  • 1 Year change-6.93%
  • Beta--
Data delayed at least 15 minutes, as of Aug 27 2024 17:52 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ZYUS Life Sciences Corporation is a Canada-based life sciences company. It develops and commercializes novel cannabinoid-based pharmaceutical drug candidates for pain management. Its lead research program is focused on developing a highly purified cannabinoid formulation to treat chronic pain due to cancer, musculoskeletal injuries and arthritis. Its pre-and non-clinical studies provide the foundation for clinical investigations of its drug candidates in humans. Its lead/first drug product candidate in this program, Trichomylin softgel capsules, is a fixed dose combination of cannabinoids formulated for treatment of chronic pain in adults. This formulation offers oral administration of highly purified cannabinoids in a controlled dosage. In parallel with the research conducted respecting Trichomylin softgel capsules, it has also identified and commenced research on a second drug candidate. This drug candidate is a cannabinoid-based therapeutic composition for pain management.

  • Revenue in CAD (TTM)428.00k
  • Net income in CAD-36.83m
  • Incorporated1944
  • Employees2.00
  • Location
    ZYUS Life Sciences Corp204 - 407 Downey RoadSASKATOON S7N 4L8CanadaCAN
  • Phone+1 (306) 242-2357
  • Fax+1 (416) 368-4440
  • Websitehttps://www.zyus.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.